Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380900 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00380900: Completed Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00380900 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00380900, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to evaluate the safety and tolerbility of ascending multiple oral doses of AGG-523 in healthy subjects and in subjects with osteoarthritis.
Interventions
- DRUG AGG-523
Trial Details
| Field | Value |
|---|---|
| Start Date | 2006-07 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
What the finished NCT00380900 record still lists
NCT00380900 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which AGG-523 is the first listed.
NCT00380900 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00380900 about?
NCT00380900 is a clinical study titled "Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy". The purpose of this study is to evaluate the safety and tolerbility of ascending multiple oral doses of AGG-523 in healthy subjects and in subjects with osteoarthritis.
What is the current status of trial NCT00380900?
This trial is currently completed. It is a Phase 1 study. The study started on 2006-07. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00380900?
The interventions under investigation include: AGG-523 (DRUG).
Who is sponsoring clinical trial NCT00380900?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia